IGC Pharma (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Apr. 29, 2024)

View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Price-to-Operating-Cash-Flow?

As of today (2024-04-29), IGC Pharma's share price is $0.458. IGC Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.11. Hence, IGC Pharma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for IGC Pharma's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, IGC Pharma's highest Price-to-Operating-Cash-Flow Ratio was 17.71. The lowest was 6.81. And the median was 12.04.

IGC's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.7
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

IGC Pharma's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.03. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.11.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -14.90% per year.

During the past 13 years, IGC Pharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 53.40% per year. The lowest was -200.00% per year. And the median was 15.20% per year.

IGC Pharma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for IGC Pharma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Price-to-Operating-Cash-Flow Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IGC Pharma's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, IGC Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Price-to-Operating-Cash-Flow falls into.

IGC Pharma Price-to-Operating-Cash-Flow Calculation

IGC Pharma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.458	/	-0.112
	=

IGC Pharma's Share Price of today is $0.458.
IGC Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

IGC Pharma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (IGC Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

IGS1:Germany

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Executives

James P Moran	director	914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch	director	14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins	director
Ram Mukunda	director, officer: Exec. Chairman & CEO
Claudia Grimaldi	officer: Vice president and PFO	PO BOX 60642, POTOMAC MD 20859
Rohit Goel	officer: Manager & PAO	PO BOX 60642, POTOMAC MD 20859
John Cherin	officer: CFO, Treasurer and PAO	662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai	director, officer: Interim CFO	4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna	director	330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy	director	10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani	director	INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd.	10 percent owner	C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii	10 percent owner	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs	10 percent owner	600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd.	10 percent owner	C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305